This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis of effectiveness appears to have been based on treatment completers only. The health outcomes estimated in the effectiveness analysis were yield and management of disease at screening; health conditions assessed through a survey measuring general health in terms of health status and prevalence of cardiovascular and respiratory diseases; general practice consultation rates; hospital admissions; certified sickness; and mortality. Baseline comparability of study groups was not clearly reported.
Effectiveness results
As regards yield and disease management at screening, at first screening an average of 2.3 diseases per person screened was found and the general practitioner did not previously know 53% of this morbidity. However, of that 53% of unknown disability, 95% was of a minor nature.
For new diseases discovered, little new therapeutic intervention was introduced. At further screening, the yield was even lower. No statistically significant differences were found in the comparison between screening and control groups in terms of health conditions, general practice consultation rates, hospital admissions, certified sickness, or mortality.
The overall consultation rate for men was 3.1% in the control group and 3.2% in the screening group, and for women 3.8% in the control group and 4% in the screening group.
The total number of admissions per 1,000 man/years at risk was 70.7 in the control group and 73.4 in the screening group.
The death rate per 1,000 man/years at risk was 9.2 in the control group and 10 in the screening group.
Clinical conclusions
The effectiveness analysis showed that multiphasic screening was as effective as conventional medical care among individuals aged between 40 and 64 years.
Measure of benefits used in the economic analysis
Health outcomes were left disaggregated and no summary benefit measure was used, thus a cost-consequences analysis was conducted. Although health outcomes were similar in the two study groups, it did not appear that the authors were willing to carry out a cost-minimisation analysis.
Direct costs
Discounting was not performed although costs were incurred over a period of nine years. Unit costs were not reported separately from quantities of resources. Only the crude average costs of screening (followed by one general practitioner consultation where necessary) were included in the analysis. The cost/resource boundary adopted in the study was not explicitly reported. The source of cost data was not reported, while resource use was retrospectively estimated in the effectiveness study. The price year was 1976.
